CAMK2A and thyroid cancer: While there have been few direct studies of CamK-A in thyroid cancer, NF-κB signaling is known to be constitutively activated in aggressive thyroid cancers, particularly those with BRAFV600E mutations, and NB-κB signaling has been shown to have increased invasive properties and poor prognosis.